OS Therapies (OSTX) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed OS Therapies (OSTX) over the past year, gaining 2.0% versus a loss of 20.6%. OS Therapies is the larger company by market cap ($75.8 million vs $73.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OSTX | PDSB |
|---|---|---|
| Share price | $1.62 | $1.02 |
| Market cap | $75.82M | $73.92M |
| 1-day change | +4.52% | -4.23% |
| YTD return | +15.71% | +32.47% |
| 1-year return | -20.59% | +2.00% |
| 5-year return | — | -91.73% |
| Forward P/E | 4.67 | — |
| EPS (TTM) | $-1.08 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.25 | $1.55 |
| 52-week low | $1.15 | $0.195 |
| Distance from 52-week high | -28.00% | -34.19% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +424.69% | +390.20% |
| Average volume | 586.70K | 23.24M |
| Shares outstanding | 46.81M | 72.47M |
| Employees | 4 | 21 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed OSTX by 22.6 percentage points over the past year.
About OS Therapies
OSTX stock →OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Healthcare · Biotechnology · 4 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Healthcare · Biotechnology · 21 employees
OSTX vs PDSB FAQ
Which is bigger, OS Therapies or PDS Biotechnology?
OS Therapies (OSTX) is larger, with a market capitalization of $75.82M compared with $73.92M for PDS Biotechnology (PDSB).
Which stock has performed better over the past year, OSTX or PDSB?
PDSB returned +2.00% over the past 12 months, compared with -20.59% for OSTX (price return, excluding dividends). Past performance does not predict future results.
Are OS Therapies and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.